Effects of Ginkgo biloba on prevention of development of experimental diabetic nephropathy in rats

Acta Pharmacol Sin. 2007 Jun;28(6):818-28. doi: 10.1111/j.1745-7254.2007.00570.x.

Abstract

Aim: To observe the preventive and therapeutic effects of Ginkgo biloba extract (GbE) on early experimental diabetic nephropathy (DN) in rats.

Methods: After an early DN model was induced by streptozotocin, rats were administered GbE at 3 doses for 12 weeks. Fasting blood glucose, creatinine (Cr), blood urea nitrogen (BUN), urine protein, kidney index, anti-oxidase, advanced glycosylation end products (AGE), collagen IV and laminin, matrix metalloproteinases-2 (MMP-2) and the tissue inhibitor of metalloproteinase-2 (TIMP-2), connective tissue growth factor (CTGF), and transforming growth factor-beta1 (TGF-beta1) mRNA were measured by different methods. The ultrastructural morphology and the thickness of glomerular base membrane (GBM) were observed by a transmission electron microscope.

Results: For the GbE-treated DN rats, when compared with the vehicle-treated DN rats, the fasting blood glucose level, Cr, BUN, urine protein level, and the intensity of oxidative stress were significantly decreased. The expression of MMP-2 greatly increased, and TIMP-2 decreased. Also, AGE, either in serum or in renal, the collagen IV, laminin, CTGF levels, and TGF-beta1 mRNA were reduced. Furthermore, both relative grades of mesangium hyperplasia by microscopical observation and the thickness of GBM by electron microscope measurement decreased significantly.

Conclusion: GbE has protective effects on several pharmacological targets in the progress of DN and is a potential drug for the prevention of early DN.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Behavior, Animal / drug effects
  • Behavior, Animal / physiology
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Captopril / therapeutic use
  • Connective Tissue Growth Factor / metabolism
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / pathology*
  • Diabetic Nephropathies / etiology
  • Diabetic Nephropathies / prevention & control*
  • Ginkgo biloba / chemistry*
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology
  • Male
  • Matrix Metalloproteinase 2 / metabolism
  • Oxidative Stress
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Tissue Inhibitor of Metalloproteinase-2 / metabolism
  • Transforming Growth Factor beta1 / genetics
  • Transforming Growth Factor beta1 / metabolism

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Blood Glucose
  • CCN2 protein, rat
  • Plant Extracts
  • Transforming Growth Factor beta1
  • Tissue Inhibitor of Metalloproteinase-2
  • Connective Tissue Growth Factor
  • Captopril
  • Matrix Metalloproteinase 2